NKGN - NKGen Biotech Inc Qarzning balans kapitallashuviga nisbati

Geopolitik keskinliklar va biomateriallar logistikasining buzilishi hozirgi vaqtda global neyroterapiya tadqiqotlariga to'sqinlik qilmoqda. Ushbu qarz va kapital nisbati grafigi ushbu qiyinchiliklarga bozorning reaksiyasini aks ettiradi, bunda 0.00 joriy metrika darajasi vazifasini o'taydi. Shu bilan birga, NKGen Biotech, Inc. (NKGN) kirish to'siqlari yuqori bo'lgan, Altsgeymer kasalligiga qarshi noyob SNK01 tizimini ishlab chiqmoqda va o'zining NK-hujayralar pipeline'i uchun klinik sinovlarning barqaror sur'atini saqlab qolmoqda.

NKGen Biotech, Inc. (NKGN) - Balans qiymatiga qarzlar 21.02.2024dan 15.03.2025gacha

NKGen Biotech Inc (NKGN) kompaniyasi koʻrsatkichlari kesimi va tahlili

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari NKGen Biotech, Inc.|NKGN - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati NKGen Biotech Corp|NKGN - Qarz va naqd pullar hisobga olingan qiymat
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar NKGen Biotech|NKGN - Kompaniyaning xususiy kapitali|Bozor qiymatining balans qiymatiga nisbati nkgenbiotech.com|NKGN - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati NKGen Biotech, Inc.|NKGN - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati NKGen|NKGN - Kompaniyaning umumiy qarzdorligi|Balans kapitallashuviga qarzlar NKGen Biotech Corp
Kompaniyaning fundamental tahlili:NKGen Biotech, Inc. - NKGN

NKGen Biotech, Inc. (NKGN) neyrodegenerativ kasalliklarga qarshi kurashish uchun innovatsion hujayra terapiyalarini ishlab chiqmoqda. Bunday tadqiqotlarning yuqori kapital intensivligi qarz va aksiyalar o'rtasidagi muvozanatni talab qiladi. Ushbu ko'rsatkich umumiy majburiyatlarning kompaniya aktivlarining balans qiymatiga nisbatini o'lchaydi. Ushbu metrikaning oshishi moliyalashtirish tuzilmasining haddan tashqari qiziganligini va kredit risklarining ortganligini bildiradi. Umumiy qarzning balans kapitaliga nisbatini tahlil qilish orqali investor dori vositalarini ishlab chiqish davrida biznesning moliyaviy barqarorligini aniqlaydi.

NKGen Biotech, Inc. kimlar bilan raqobatlashadi

Qarzning balans qiymatiga nisbati BIIB (Biogen Inc.)|neurocrine.com - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Regencell Bioscience Holdings Limited (RGC)|AXSM: Qarzning sof aktivlarga nisbati|Qarzning balans kapitallashuviga nisbati ACAD|XENE (Xenon Corp) - Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati Viking Therapeutics (VKTX)|Qarzning balans qiymatiga nisbati SUPN|Qarzning balans kapitallashuviga nisbati CPRX|Balans kapitallashuviga qarzlar Denali (DNLI)|HRMY (Harmony Pharma) - Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati Biohaven Corp BHVN|AMLX (Amylyx Pharmaceuticals) - Balans kapitallashuviga qarzlar|TRVI: Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati Praxis Precision Medicines, Inc.|Qarzning balans qiymatiga nisbati Anavex|CBLL - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati prothena.com|Balans kapitallashuviga qarzlar Alector, Inc. (ALEC)|Qarzning balans kapitallashuviga nisbati annexonbio.com (ANNX)|Balans kapitallashuviga qarzlar OMER|Neurogene Inc - Sof aktivlarga qarzlar|ACIU (AC Immune Corp) - Qarzning balans kapitallashuviga nisbati|Voyager Corp (VYGR) - Balans qiymatiga qarzlar|NMRA - Qarzning balans qiymatiga nisbati|scilexholding.com (SCLX) - Qarzning balans kapitaliga nisbati|Balans kapitallashuviga qarzlar TVGN (Tevogen Bio)|Balans qiymatiga qarzlar Alpha Cognition Corp|Balans kapitallashuviga qarzlar CGTX (Cognition Therapeutics)|Qarzning balans qiymatiga nisbati Inhibikase Pharma (IKT)|Balans kapitallashuviga qarzlar Cassava Sciences, Inc.|ASRT - Qarzning sof aktivlarga nisbati|Qarzning balans qiymatiga nisbati Coya (COYA)|VTGN - Qarzning sof aktivlarga nisbati|ovidrx.com - Balans kapitallashuviga qarzlar|ABOS (Acumen Pharmaceuticals, Inc) - Sof aktivlarga qarzlar|Qarzning balans kapitallashuviga nisbati CervoMed Inc. (CRVO)|Qarzning balans qiymatiga nisbati Alterity Therapeutics Ltd|Balans kapitallashuviga qarzlar CLNN (Clene Inc.)|Qarzning balans qiymatiga nisbati pepgen.com PEPG|Qarzning balans qiymatiga nisbati JUNS|Relmada Corp - Sof aktivlarga qarzlar|Annovis Bio, Inc. (ANVS) - Qarzning balans kapitallashuviga nisbati|GRCE: Qarzning balans qiymatiga nisbati|AIFF: Qarzning balans kapitallashuviga nisbati|Klotho Neurosciences (KLTO) - Balans kapitallashuviga qarzlar|NeuroSense Therapeutics Ltd - Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati RVPH|Qarzning balans kapitallashuviga nisbati MetaVia Inc MTVA|Qarzning balans qiymatiga nisbati NRXS (neuraxis.com)|HSDT - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati Passage Bio Inc. PASG|NEUP (Neuphoria) - Balans kapitallashuviga qarzlar|Minerva (NERV) - Balans qiymatiga qarzlar|ATHA: Qarzning balans qiymatiga nisbati|ADXN (addextherapeutics.com) - Balans kapitallashuviga qarzlar|ALZN - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati CYCN|Protagenic Therapeutics - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar KTTA (pasitheaclinics.com)|CRGT - Qarzning balans kapitallashuviga nisbati|avenuetx.com - Qarzning balans qiymatiga nisbati|BrainStorm Cell Therapeutics - Qarzning balans kapitallashuviga nisbati|CARA - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar CHRO (Chromocell Therapeutics Corporation)|Eliem Therapeutics Inc. (ELYM) - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar ITCI (Intra-Cellular Therapies Inc.)|Balans qiymatiga qarzlar LBPH|Qarzning balans kapitallashuviga nisbati Marinus Pharmaceuticals, Inc. MRNS|Qarzning balans qiymatiga nisbati NeuroBo Pharmaceuticals Inc NRBO|Qarzning balans qiymatiga nisbati Sage Therapeutics, Inc|Qarzning sof aktivlarga nisbati Synaptogenix, Inc SNPX|TRVN - Balans kapitallashuviga qarzlar|VIGL - Qarzning balans kapitallashuviga nisbati|Anew Medical - Balans kapitallashuviga qarzlar|CERE (Cerevel Therapeutics Inc) - Sof aktivlarga qarzlar